← Leaderboards
Chinghai Kao
University Of Virginia Charlottesville
$3,858,376
Attributed
$3,858,376
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $552.9K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$3,858,376 · 4
By mechanism
R01$3,642,524 · 3
R29$215,852 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Patricia Jean Hollen$2,532,310
- Sidney Michael Hecht$6,822,120
- Allen D Everett$14,760,201
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyTransfection /Expression VectorLuciferasesGrowthInjection Of Therapeutic AgentKillingsEnhancersCellsCancer CellGlutamate Carboxypeptidase IiHormone Refractory Prostate CancerAndrogensIn VitroIn VivoAdenovirusesCell TypeClinical TrialsDiagnosisAblationBaseAndrogen Independent Prostate CancerGenesAdenoviridaeHerpes Simplex Infections
Grant awards (16)
Replicative Adenovirus and Anti-angiogenic Therapy$279,215
R01 · FY2011 · CA · contact PI
Replicative Adenovirus and Anti-angiogenic Therapy$287,850
R01 · FY2010 · CA · contact PI
Replicative Adenovirus and Anti-angiogenic Therapy$287,850
R01 · FY2009 · CA · contact PI
Replicative Adenovirus and Anti-angiogenic Therapy$287,850
R01 · FY2008 · CA · contact PI
Tissue Specific Gene Therapy for Human Prostate Cancer$265,033
R01 · FY2008 · CA · contact PI
Replicative Adenovirus and Anti-angiogenic Therapy$287,850
R01 · FY2007 · CA · contact PI
Tissue Specific Gene Therapy for Human Prostate Cancer$265,033
R01 · FY2007 · CA · contact PI
Tissue Specific Gene Therapy for Human Prostate Cancer$272,949
R01 · FY2006 · CA · contact PI
Tissue Specific Gene Therapy for Human Prostate Cancer$279,518
R01 · FY2005 · CA
Tissue Specific Gene Therapy for Human Prostate Cancer$279,518
R01 · FY2004 · CA
TISSUE SPECIFIC GENE THERAPY FOR PULMONARY METASTASIS$283,286
R01 · FY2003 · CA
TISSUE SPECIFIC GENE THERAPY FOR PULMONARY METASTASIS$283,286
R01 · FY2002 · CA
TISSUE SPECIFIC GENE THERAPY FOR PULMONARY METASTASIS$283,286
R01 · FY2001 · CA
TISSUE SPECIFIC GENE THERAPY FOR HUMAN PROSTATE CANCER$109,429
R29 · FY2001 · CA
TISSUE SPECIFIC GENE THERAPY FOR HUMAN PROSTATE CANCER$88,366
R29 · FY2000 · CA
TISSUE SPECIFIC GENE THERAPY FOR HUMAN PROSTATE CANCER$18,057
R29 · FY2000 · CA